UBS AM
MCRB icon

UBS AM’s Seres Therapeutics MCRB Stock Holding History

UBS AM’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,705
Closed -$224K – 2578
2023
Q3 		$224K Hold
4,705
– – ﹤0.01% 2495
2023
Q2 		$534K Hold
4,705
– – ﹤0.01% 2296
2023
Q1 		$534K Buy
4,705
+587
+14% +$63.5K ﹤0.01% 2296
2022
Q4 		$461K Hold
4,118
– – ﹤0.01% 2201
2022
Q3 		$529K Sell
4,118
-886
-18% -$90.7K ﹤0.01% 2326
2022
Q2 		$343K Buy
5,004
+971
+24% +$83.7K ﹤0.01% 2432
2022
Q1 		$574K Buy
4,033
+2
+0% +$308 ﹤0.01% 2418
2021
Q4 		$672K Sell
4,031
-17,504
-81% -$2.78M ﹤0.01% 2416
2021
Q3 		$3M Buy
21,535
+17,032
+378% +$3.33M ﹤0.01% 1638
2021
Q2 		$2.15M Buy
4,503
+902
+25% +$381K ﹤0.01% 1811
2021
Q1 		$1.48M Buy
3,601
+449
+14% +$207K ﹤0.01% 1888
2020
Q4 		$1.54M Buy
+3,152
New +$1.85M ﹤0.01% 1786
2019
Q2 		– Sell
-526
Closed -$72.3K – 2869
2019
Q1 		$72.3K Buy
+526
New +$64.1K ﹤0.01% 2588
2016
Q4 		– Sell
-6,686
Closed -$1.64M – 2586
2016
Q3 		$1.64M Sell
6,686
-530
-7% -$186K ﹤0.01% 1453
2016
Q2 		$4.19M Buy
7,216
+2,788
+63% +$1.64M ﹤0.01% 1066
2016
Q1 		$2.35M Buy
4,428
+77
+2% +$40.2K ﹤0.01% 1307
2015
Q4 		$3.05M Sell
4,351
-421
-9% -$277K ﹤0.01% 1244
2015
Q3 		$2.83M Buy
4,772
+1,362
+40% +$1.11M ﹤0.01% 1270
2015
Q2 		$2.83M Buy
+3,410
New +$2.98M ﹤0.01% 1244

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's MCRB Position: Q4 2023 in Review

UBS AM sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 4,705 shares — an estimated $224K sold.

UBS AM first reported a position in MCRB in Q2 2015 and held it in 19 quarters. The position peaked at $4.19M in Q2 2016. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • UBS AM reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • UBS AM sold 4,705 Seres Therapeutics shares in Q4 2023, an estimated $224K.
  • UBS AM first reported a position in Seres Therapeutics in Q2 2015 and held it in 19 quarters.
  • UBS AM's Seres Therapeutics position peaked at $4.19M in Q2 2016.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on UBS AM's 13F filing for Q4 2023, filed 14 Feb 2024.